Analyzing Whether Pharmacogenetics in Psychiatric Patients with Polypharmacy Can Identify Increased Medication Adverse Effects and Improve Outcomes


About this study

The purpose of this study is to test whether pharmacogenetics in psychiatric patients with polypharmacy can identify increased medication adverse effects and improve outcomes.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Ages 18 and older.
  • Hospitalized on Generose 2E (Acute Care Psychiatry), 3E (Medical and Geriatric Psychiatry), or 3W (Mood Disorders Unit).
  • A voluntary patient.
  • Having 5 or more medications (scheduled or as needed) on their medication list.
  • Ability to give informed consent.

Exclusion Criteria

  • Patients with cognitive impairments such as moderate to severe dementia.
  • Patients who do not communicate in English or cannot comprehend the rating scales used.
  • Patients who have had pharmacogenetics testing performed within the previous 5 years.
  • Patients who deny permission to communicate the PGx results with their outpatient provider.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Simon Kung, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer